Noxopharm (ASX:NOX) has reached a significant milestone in its first-in-human trial of SOF-SKN, announcing that the initial multiple-dose cohort in the HERACLES study has been completed with no safety concerns identified. …
Noxopharm advances autoimmune candidate as first multiple-dose cohort clears safety review
December 3, 2025 Australian Biotech
Latest Video
New Stories
-
Island Pharmaceuticals secures boost as directors and major shareholders exercise options
December 3, 2025 - - Australian Biotech -
BCAL launches national registry to track real-world impact of BREASTESTplus
December 3, 2025 - - Australian Biotech -
Noxopharm advances autoimmune candidate as first multiple-dose cohort clears safety review
December 3, 2025 - - Australian Biotech -
Cost of multiple sclerosis in Australia surges as prevalence accelerates
December 3, 2025 - - Latest News -
Australia can increase prices in response to pressure, as it did just 36 months ago for 950 medicines
December 2, 2025 - - Latest News -
Reforming Australia’s Opioid Dependence Treatment Program - From red tape to person-centred care
December 2, 2025 - - Latest News -
Novo Nordisk raises over $106,000 for Type 1 Diabetes research
December 2, 2025 - - Latest News